Please assess the completion status of the following clinical trial:

Trial Title: Influence of Esmolol on a Closed-Loop Anesthesia System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male patients scheduled for a general anesthesia~Exclusion Criteria:~* age lower than 18 years~* allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or to morphine, or to a myorelaxant or to an excipient,~* any other history of anaphylactic reaction,~* hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,~* hypersensibility to esmolol or to an excipient,~* history of central nervous system disease,~* patients receiving a psychotropic treatment or an agonist-antagonist opiate,~* hypovolemic patients,~* patients receiving a cardio-vascular treatment,~* patients with a pacemaker,~* expected bleeding more than 20% of the blood volume,~* simultaneous general and loco-regional anesthesia,~* patients suffering from asthma, COPD, trouble of the heart rhythm or conduction, cardiac insufficiency, cardiogenogenic shock, Prinzmetal syndrome, pheochromocytoma,~* patients with a heart rate less than 50/min and/or an arterial hypotension,~* neurosurgical act or any other which precludes an adequate positioning of the bispectral electrode.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
- Esmolol (Type: EXPERIMENTAL): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol

Based on this trial design, predict the completion outcome and termination type (if applicable).